Vouched and Verisart Partner to Provide Peace of Mind for NFT Artists, Investors
13.4.2021 13:00:00 EEST | Business Wire | Press release
Power to the Beeple, and to every other artist, collector, and investor working to expand the boundaries of fine art by bringing works tied to nonfungible tokens (NFTs) to the mainstream.
Vouched and Verisart today announced an industry-first partnership to apply Vouched’s unique digital identity verification technology to Verisart’s first-of-its-kind blockchain certification platform for digital artists and collectors. The partnership is a significant step forward for the NFT art industry, which has recently seen spikes in interest after a piece created by artist Beeple sold for $69.3 million, a new record for purely digital work.
“The rise of NFTs demonstrates that virtually everything in our known history can be adapted to a digital future, from healthcare to banking to real estate, and now fine art,” said John Baird, Co-Founder, and CEO of Vouched. “Identity verification is absolutely foundational to every element of this ongoing digital revolution. We are excited to work with Verisart to bring Vouched’s unmatched AI technology to the world of NFT art, helping to unleash creativity for artists and enable more confident investing for collectors.”
Vouched’s identity verification platform will be used as part of Verisart’s new patent-pending global standard for digital art certification, enabling creators, collectors, and dealers to easily create digital certificates registered on the blockchain.
“While there may be a lot of hype around the NFT art market right now, it highlights an important advancement that is here to stay and will continue to reshape how we create, authenticate and value those creations moving forward,” said Robert Norton, CEO of Verisart. “Verisart is pioneering the capability to apply blockchain to certification in the art and collectibles market. We support creativity by facilitating trusted transactions and empowering artists to establish their careers and legacies, regardless of what their works sell for.”
Starting immediately, artists can create secure certificates of authenticity for their NFTs on Verisart using Vouched’s platform by using their ID and Vouched’s facial recognition tools to ensure they are who they say they are. The same process is being utilized for collectors on Verisart to verify purchaser identity, creating an extra layer of security for both the artist and the buyer.
About Vouched
Vouched is proprietary artificial intelligence and computer vision that powers end-to-end visual identity verification and fraud detection online in real-time. An expert on more than 450 government-issued identity documents, including driver’s licenses, passports, and permanent resident cards, in 50+ countries, Vouched helps banks, gig and sharing companies, and hospital and healthcare providers verify and onboard users to provide access to life’s most critical services instantly.
For more information on Vouched, visit www.vouched.id, or contact Vouched communications at 1-800-674-8798 or press@vouched.id.
About Verisart
Verisart is an award-winning certification service enabling artists, galleries, and collectors to create certificates of authenticity securely registered on the blockchain. Founded in 2015 as the first company to apply blockchain to certification in the art and collectibles market, Verisart has pioneered a new patent-pending global standard for certification. Over 20,000 artworks have been certified on the platform by more than 5000 artists including Shepard Fairey, Ai Weiwei, Jules De Balincourt, Penny Slinger, and Derek Boshier.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005446/en/
Contact information
Danny Kerth
Danny.Kerth@fleishman.com
314.570.0090
Janna Nallet
janna@consortpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
